Molecular mechanisms of FK506-induced hypertension in solid organ transplantation patients
Objective Tacrolimus (FK506) is an immunosuppressive drug, which is widely used to prevent rejection of transplanted organs. However, chronic administration of FK506 leads to hypertension in solid organ transplantation patients, and its molecular mechanisms are much more complicated. In this review,...
Gespeichert in:
Veröffentlicht in: | Chinese medical journal 2014, Vol.127 (20), p.3645-3650 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3650 |
---|---|
container_issue | 20 |
container_start_page | 3645 |
container_title | Chinese medical journal |
container_volume | 127 |
creator | Wang, Jianglin Guo, Ren Liu, Shikun Chen, Qingjie Zuo, Shanru Yang, Meng Zuo, Xiaocong |
description | Objective Tacrolimus (FK506) is an immunosuppressive drug, which is widely used to prevent rejection of transplanted organs. However, chronic administration of FK506 leads to hypertension in solid organ transplantation patients, and its molecular mechanisms are much more complicated. In this review, we will discuss the above-mentioned molecular mechanisms of FK506-induced hypertension in solid organ transplantation subjects. Data sources The data analyzed in this review were mainly from relevant articles without restriction on the publication date reported in PubMed. The terms "FK506" or "tacrolimus" and "hypertension"were used for the literature search. Study selection Original articles with no limitation of research design and critical reviews containing data relevant to FK506-induced hypertension and its molecular mechanisms were retrieved, reviewed and analyzed. Results There are several molecular mechanisms attributed to FK506-induced hypertension in solid organ transplantation subjects. First, FK506 binds FK506 binding protein 12 and its related isoform 12.6 (FKBP12/12.6) and removes them from intracellular ryanodine receptors that induce a calcium ion leakage from the endoplasmic/sarcoplasmic reticulum. The conventional protein kinase C beta II (cPKCI311)-mediated phosphorylation of endothelial nitric oxide (NO) synthase at Thr495, which reduces the production of NO, was activated by calcium ion leakage. Second, transforming growth factor receptodSMAD2/3 signaling activation plays an important role in Treg/Th17 cell imbalance in T cells which toget converge to cause inflammation, endothelial dysfunction, and hypertension following tacrolimus treatment. Third, the activation of with-no-K(Lys) kinases/STE20/SPSl-related proline/alanine-rich kinase/thiazide-sensitive sodium chloride co-transporter (WNKs/SPAK/NCC) pathway has a central role in tacrolimus-induced hypertension. Finally, the enhanced activity of renal renin-angiotensin-aldosterone system seems to play a crucial role in the pathophysiology of FK506-induced hypertension. Conclusion FK506 plays a predominant role in the pathophShysiology of hypertension in solid organ transplantation subjects. |
doi_str_mv | 10.3760/cma.j.issn.0366-6999.20141176 |
format | Article |
fullrecord | <record><control><sourceid>wanfang_jour_proqu</sourceid><recordid>TN_cdi_wanfang_journals_zhcmj201420022</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>662852132</cqvip_id><wanfj_id>zhcmj201420022</wanfj_id><sourcerecordid>zhcmj201420022</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-92e294eef5eb09fdcb3a9a2231a8f23993d685f9db4533433ea2b2391e0359d03</originalsourceid><addsrcrecordid>eNo9kUFv1DAQhS0EokvhL6AICcQlwZ6JvfGBA6ooIIq4wIWL5TjOrqPETu1EqPx6HO1uTyN5vpk3fo-Qt4xWuBf0g5l0NVQuJV9RFKIUUsoKKKsZ24snZAe8hpKLmj0lu0fgirxIaaAUON-L5-QKODIBNe7Inx9htGYddSwma47auzSlIvTF7XdORel8txrbFceH2cbF-uSCL5wvUhhdV4R40L5YovZpHrVf9LK151ysX9JL8qzXY7KvzvWa_L79_Ovma3n388u3m093pamxWUoJFmRtbc9tS2XfmRa11ADIdNMDSomdaHgvu7bmiDWi1dDmd2YpctlRvCbvTnv_at9rf1BDWKPPiurf0UzD5g3kr0MG35_AOYb71aZFTS4ZO-bTbViTYoKBbDjuWUY_nlATQ0rR9mqObtLxQTGqthxUzkENastBbTarzWZ1ySHPvz5Lre1ku8fpi_EZeHMWOAZ_uHf57AsjBDQcGAL-B_h8kp4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1612985371</pqid></control><display><type>article</type><title>Molecular mechanisms of FK506-induced hypertension in solid organ transplantation patients</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Wang, Jianglin ; Guo, Ren ; Liu, Shikun ; Chen, Qingjie ; Zuo, Shanru ; Yang, Meng ; Zuo, Xiaocong</creator><creatorcontrib>Wang, Jianglin ; Guo, Ren ; Liu, Shikun ; Chen, Qingjie ; Zuo, Shanru ; Yang, Meng ; Zuo, Xiaocong</creatorcontrib><description>Objective Tacrolimus (FK506) is an immunosuppressive drug, which is widely used to prevent rejection of transplanted organs. However, chronic administration of FK506 leads to hypertension in solid organ transplantation patients, and its molecular mechanisms are much more complicated. In this review, we will discuss the above-mentioned molecular mechanisms of FK506-induced hypertension in solid organ transplantation subjects. Data sources The data analyzed in this review were mainly from relevant articles without restriction on the publication date reported in PubMed. The terms "FK506" or "tacrolimus" and "hypertension"were used for the literature search. Study selection Original articles with no limitation of research design and critical reviews containing data relevant to FK506-induced hypertension and its molecular mechanisms were retrieved, reviewed and analyzed. Results There are several molecular mechanisms attributed to FK506-induced hypertension in solid organ transplantation subjects. First, FK506 binds FK506 binding protein 12 and its related isoform 12.6 (FKBP12/12.6) and removes them from intracellular ryanodine receptors that induce a calcium ion leakage from the endoplasmic/sarcoplasmic reticulum. The conventional protein kinase C beta II (cPKCI311)-mediated phosphorylation of endothelial nitric oxide (NO) synthase at Thr495, which reduces the production of NO, was activated by calcium ion leakage. Second, transforming growth factor receptodSMAD2/3 signaling activation plays an important role in Treg/Th17 cell imbalance in T cells which toget converge to cause inflammation, endothelial dysfunction, and hypertension following tacrolimus treatment. Third, the activation of with-no-K(Lys) kinases/STE20/SPSl-related proline/alanine-rich kinase/thiazide-sensitive sodium chloride co-transporter (WNKs/SPAK/NCC) pathway has a central role in tacrolimus-induced hypertension. Finally, the enhanced activity of renal renin-angiotensin-aldosterone system seems to play a crucial role in the pathophysiology of FK506-induced hypertension. Conclusion FK506 plays a predominant role in the pathophShysiology of hypertension in solid organ transplantation subjects.</description><identifier>ISSN: 0366-6999</identifier><identifier>EISSN: 2542-5641</identifier><identifier>DOI: 10.3760/cma.j.issn.0366-6999.20141176</identifier><identifier>PMID: 25316243</identifier><language>eng</language><publisher>China: Department of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China</publisher><subject>FK506 ; FKBP12 ; Humans ; Hypertension - chemically induced ; Immunosuppressive Agents - adverse effects ; Immunosuppressive Agents - therapeutic use ; Organ Transplantation - adverse effects ; Tacrolimus - adverse effects ; Tacrolimus - therapeutic use ; 分子机制 ; 器官移植 ; 妊高征 ; 实体 ; 患者 ; 蛋白激酶C</subject><ispartof>Chinese medical journal, 2014, Vol.127 (20), p.3645-3650</ispartof><rights>Copyright © Wanfang Data Co. Ltd. All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-92e294eef5eb09fdcb3a9a2231a8f23993d685f9db4533433ea2b2391e0359d03</citedby><cites>FETCH-LOGICAL-c438t-92e294eef5eb09fdcb3a9a2231a8f23993d685f9db4533433ea2b2391e0359d03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/85656X/85656X.jpg</thumbnail><link.rule.ids>314,780,784,864,4022,27922,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25316243$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Jianglin</creatorcontrib><creatorcontrib>Guo, Ren</creatorcontrib><creatorcontrib>Liu, Shikun</creatorcontrib><creatorcontrib>Chen, Qingjie</creatorcontrib><creatorcontrib>Zuo, Shanru</creatorcontrib><creatorcontrib>Yang, Meng</creatorcontrib><creatorcontrib>Zuo, Xiaocong</creatorcontrib><title>Molecular mechanisms of FK506-induced hypertension in solid organ transplantation patients</title><title>Chinese medical journal</title><addtitle>Chinese Medical Journal</addtitle><description>Objective Tacrolimus (FK506) is an immunosuppressive drug, which is widely used to prevent rejection of transplanted organs. However, chronic administration of FK506 leads to hypertension in solid organ transplantation patients, and its molecular mechanisms are much more complicated. In this review, we will discuss the above-mentioned molecular mechanisms of FK506-induced hypertension in solid organ transplantation subjects. Data sources The data analyzed in this review were mainly from relevant articles without restriction on the publication date reported in PubMed. The terms "FK506" or "tacrolimus" and "hypertension"were used for the literature search. Study selection Original articles with no limitation of research design and critical reviews containing data relevant to FK506-induced hypertension and its molecular mechanisms were retrieved, reviewed and analyzed. Results There are several molecular mechanisms attributed to FK506-induced hypertension in solid organ transplantation subjects. First, FK506 binds FK506 binding protein 12 and its related isoform 12.6 (FKBP12/12.6) and removes them from intracellular ryanodine receptors that induce a calcium ion leakage from the endoplasmic/sarcoplasmic reticulum. The conventional protein kinase C beta II (cPKCI311)-mediated phosphorylation of endothelial nitric oxide (NO) synthase at Thr495, which reduces the production of NO, was activated by calcium ion leakage. Second, transforming growth factor receptodSMAD2/3 signaling activation plays an important role in Treg/Th17 cell imbalance in T cells which toget converge to cause inflammation, endothelial dysfunction, and hypertension following tacrolimus treatment. Third, the activation of with-no-K(Lys) kinases/STE20/SPSl-related proline/alanine-rich kinase/thiazide-sensitive sodium chloride co-transporter (WNKs/SPAK/NCC) pathway has a central role in tacrolimus-induced hypertension. Finally, the enhanced activity of renal renin-angiotensin-aldosterone system seems to play a crucial role in the pathophysiology of FK506-induced hypertension. Conclusion FK506 plays a predominant role in the pathophShysiology of hypertension in solid organ transplantation subjects.</description><subject>FK506</subject><subject>FKBP12</subject><subject>Humans</subject><subject>Hypertension - chemically induced</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Organ Transplantation - adverse effects</subject><subject>Tacrolimus - adverse effects</subject><subject>Tacrolimus - therapeutic use</subject><subject>分子机制</subject><subject>器官移植</subject><subject>妊高征</subject><subject>实体</subject><subject>患者</subject><subject>蛋白激酶C</subject><issn>0366-6999</issn><issn>2542-5641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kUFv1DAQhS0EokvhL6AICcQlwZ6JvfGBA6ooIIq4wIWL5TjOrqPETu1EqPx6HO1uTyN5vpk3fo-Qt4xWuBf0g5l0NVQuJV9RFKIUUsoKKKsZ24snZAe8hpKLmj0lu0fgirxIaaAUON-L5-QKODIBNe7Inx9htGYddSwma47auzSlIvTF7XdORel8txrbFceH2cbF-uSCL5wvUhhdV4R40L5YovZpHrVf9LK151ysX9JL8qzXY7KvzvWa_L79_Ovma3n388u3m093pamxWUoJFmRtbc9tS2XfmRa11ADIdNMDSomdaHgvu7bmiDWi1dDmd2YpctlRvCbvTnv_at9rf1BDWKPPiurf0UzD5g3kr0MG35_AOYb71aZFTS4ZO-bTbViTYoKBbDjuWUY_nlATQ0rR9mqObtLxQTGqthxUzkENastBbTarzWZ1ySHPvz5Lre1ku8fpi_EZeHMWOAZ_uHf57AsjBDQcGAL-B_h8kp4</recordid><startdate>2014</startdate><enddate>2014</enddate><creator>Wang, Jianglin</creator><creator>Guo, Ren</creator><creator>Liu, Shikun</creator><creator>Chen, Qingjie</creator><creator>Zuo, Shanru</creator><creator>Yang, Meng</creator><creator>Zuo, Xiaocong</creator><general>Department of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>2B.</scope><scope>4A8</scope><scope>92I</scope><scope>93N</scope><scope>PSX</scope><scope>TCJ</scope></search><sort><creationdate>2014</creationdate><title>Molecular mechanisms of FK506-induced hypertension in solid organ transplantation patients</title><author>Wang, Jianglin ; Guo, Ren ; Liu, Shikun ; Chen, Qingjie ; Zuo, Shanru ; Yang, Meng ; Zuo, Xiaocong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-92e294eef5eb09fdcb3a9a2231a8f23993d685f9db4533433ea2b2391e0359d03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>FK506</topic><topic>FKBP12</topic><topic>Humans</topic><topic>Hypertension - chemically induced</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Organ Transplantation - adverse effects</topic><topic>Tacrolimus - adverse effects</topic><topic>Tacrolimus - therapeutic use</topic><topic>分子机制</topic><topic>器官移植</topic><topic>妊高征</topic><topic>实体</topic><topic>患者</topic><topic>蛋白激酶C</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Jianglin</creatorcontrib><creatorcontrib>Guo, Ren</creatorcontrib><creatorcontrib>Liu, Shikun</creatorcontrib><creatorcontrib>Chen, Qingjie</creatorcontrib><creatorcontrib>Zuo, Shanru</creatorcontrib><creatorcontrib>Yang, Meng</creatorcontrib><creatorcontrib>Zuo, Xiaocong</creatorcontrib><collection>中文科技期刊数据库</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Wanfang Data Journals - Hong Kong</collection><collection>WANFANG Data Centre</collection><collection>Wanfang Data Journals</collection><collection>万方数据期刊 - 香港版</collection><collection>China Online Journals (COJ)</collection><collection>China Online Journals (COJ)</collection><jtitle>Chinese medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Jianglin</au><au>Guo, Ren</au><au>Liu, Shikun</au><au>Chen, Qingjie</au><au>Zuo, Shanru</au><au>Yang, Meng</au><au>Zuo, Xiaocong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular mechanisms of FK506-induced hypertension in solid organ transplantation patients</atitle><jtitle>Chinese medical journal</jtitle><addtitle>Chinese Medical Journal</addtitle><date>2014</date><risdate>2014</risdate><volume>127</volume><issue>20</issue><spage>3645</spage><epage>3650</epage><pages>3645-3650</pages><issn>0366-6999</issn><eissn>2542-5641</eissn><abstract>Objective Tacrolimus (FK506) is an immunosuppressive drug, which is widely used to prevent rejection of transplanted organs. However, chronic administration of FK506 leads to hypertension in solid organ transplantation patients, and its molecular mechanisms are much more complicated. In this review, we will discuss the above-mentioned molecular mechanisms of FK506-induced hypertension in solid organ transplantation subjects. Data sources The data analyzed in this review were mainly from relevant articles without restriction on the publication date reported in PubMed. The terms "FK506" or "tacrolimus" and "hypertension"were used for the literature search. Study selection Original articles with no limitation of research design and critical reviews containing data relevant to FK506-induced hypertension and its molecular mechanisms were retrieved, reviewed and analyzed. Results There are several molecular mechanisms attributed to FK506-induced hypertension in solid organ transplantation subjects. First, FK506 binds FK506 binding protein 12 and its related isoform 12.6 (FKBP12/12.6) and removes them from intracellular ryanodine receptors that induce a calcium ion leakage from the endoplasmic/sarcoplasmic reticulum. The conventional protein kinase C beta II (cPKCI311)-mediated phosphorylation of endothelial nitric oxide (NO) synthase at Thr495, which reduces the production of NO, was activated by calcium ion leakage. Second, transforming growth factor receptodSMAD2/3 signaling activation plays an important role in Treg/Th17 cell imbalance in T cells which toget converge to cause inflammation, endothelial dysfunction, and hypertension following tacrolimus treatment. Third, the activation of with-no-K(Lys) kinases/STE20/SPSl-related proline/alanine-rich kinase/thiazide-sensitive sodium chloride co-transporter (WNKs/SPAK/NCC) pathway has a central role in tacrolimus-induced hypertension. Finally, the enhanced activity of renal renin-angiotensin-aldosterone system seems to play a crucial role in the pathophysiology of FK506-induced hypertension. Conclusion FK506 plays a predominant role in the pathophShysiology of hypertension in solid organ transplantation subjects.</abstract><cop>China</cop><pub>Department of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China</pub><pmid>25316243</pmid><doi>10.3760/cma.j.issn.0366-6999.20141176</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0366-6999 |
ispartof | Chinese medical journal, 2014, Vol.127 (20), p.3645-3650 |
issn | 0366-6999 2542-5641 |
language | eng |
recordid | cdi_wanfang_journals_zhcmj201420022 |
source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals |
subjects | FK506 FKBP12 Humans Hypertension - chemically induced Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use Organ Transplantation - adverse effects Tacrolimus - adverse effects Tacrolimus - therapeutic use 分子机制 器官移植 妊高征 实体 患者 蛋白激酶C |
title | Molecular mechanisms of FK506-induced hypertension in solid organ transplantation patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T18%3A27%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wanfang_jour_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20mechanisms%20of%20FK506-induced%20hypertension%20in%20solid%20organ%20transplantation%20patients&rft.jtitle=Chinese%20medical%20journal&rft.au=Wang,%20Jianglin&rft.date=2014&rft.volume=127&rft.issue=20&rft.spage=3645&rft.epage=3650&rft.pages=3645-3650&rft.issn=0366-6999&rft.eissn=2542-5641&rft_id=info:doi/10.3760/cma.j.issn.0366-6999.20141176&rft_dat=%3Cwanfang_jour_proqu%3Ezhcmj201420022%3C/wanfang_jour_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1612985371&rft_id=info:pmid/25316243&rft_cqvip_id=662852132&rft_wanfj_id=zhcmj201420022&rfr_iscdi=true |